Eaton Vance Management boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 66.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 96,497 shares of the life sciences company’s stock after purchasing an additional 38,508 shares during the quarter. Eaton Vance Management owned about 0.07% of Illumina worth $28,942,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in ILMN. Oregon Public Employees Retirement Fund boosted its position in Illumina by 66,581.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock worth $35,000 after purchasing an additional 10,546,495 shares during the period. Capital International Investors bought a new position in Illumina during the third quarter worth $1,482,837,000. Canada Pension Plan Investment Board boosted its position in Illumina by 272.2% during the third quarter. Canada Pension Plan Investment Board now owns 1,023,452 shares of the life sciences company’s stock worth $375,668,000 after purchasing an additional 748,500 shares during the period. Jennison Associates LLC lifted its holdings in shares of Illumina by 13.5% during the fourth quarter. Jennison Associates LLC now owns 5,479,564 shares of the life sciences company’s stock worth $1,643,486,000 after buying an additional 653,348 shares in the last quarter. Finally, WCM Investment Management CA acquired a new stake in shares of Illumina during the third quarter worth $77,035,000. 90.32% of the stock is owned by hedge funds and other institutional investors.
In other news, Director Robert S. Epstein sold 1,345 shares of the business’s stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $343.57, for a total transaction of $462,101.65. Following the sale, the director now directly owns 6,101 shares in the company, valued at $2,096,120.57. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Charles Dadswell sold 124 shares of the business’s stock in a transaction dated Wednesday, January 2nd. The stock was sold at an average price of $294.71, for a total value of $36,544.04. Following the sale, the senior vice president now owns 7,003 shares in the company, valued at $2,063,854.13. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 39,863 shares of company stock worth $12,169,374. Company insiders own 0.54% of the company’s stock.
A number of equities research analysts have recently weighed in on ILMN shares. Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a report on Monday, December 31st. UBS Group raised Illumina from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $340.00 to $370.00 in a report on Thursday, January 3rd. Morgan Stanley dropped their target price on Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a report on Monday, January 7th. Deutsche Bank downgraded Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price for the company. in a report on Friday, January 25th. Finally, BidaskClub downgraded Illumina from a “hold” rating to a “sell” rating in a research note on Tuesday, January 29th. Five analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Illumina presently has a consensus rating of “Buy” and a consensus target price of $346.40.
Illumina stock opened at $296.88 on Friday. The stock has a market capitalization of $44.43 billion, a price-to-earnings ratio of 52.84, a price-to-earnings-growth ratio of 2.16 and a beta of 1.20. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 0.23. Illumina, Inc. has a 12-month low of $221.49 and a 12-month high of $372.61.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.04). The firm had revenue of $867.00 million for the quarter, compared to the consensus estimate of $865.33 million. Illumina had a return on equity of 24.51% and a net margin of 24.79%. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.44 earnings per share. As a group, equities analysts anticipate that Illumina, Inc. will post 6.52 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first published by Zolmax and is owned by of Zolmax. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://zolmax.com/investing/illumina-inc-ilmn-shares-bought-by-eaton-vance-management/2918811.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
See Also: What are municipal bonds?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.